<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589299</url>
  </required_header>
  <id_info>
    <org_study_id>AUH-2018-100</org_study_id>
    <secondary_id>2018-003592-34</secondary_id>
    <nct_id>NCT04589299</nct_id>
  </id_info>
  <brief_title>Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)</brief_title>
  <acronym>SIDEC</acronym>
  <official_title>Randomized, Parallel Study of Subcutaneous Versus Intravenous Immunoglobulin in Treatment-naïve Patients With Chronic Inflammatory Demyelinating Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SIDEC - (Subcutaneous Immunoglobulin in De-novo CIDP) ia a study designed as a randomized,&#xD;
      parallel study with an open-label extension phase. The aims are to compare the effect of SCIG&#xD;
      and IVIG in 60 treatment-naïve CIDP patients, and to detect the lowest effective dosage for&#xD;
      maintenance treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In fase I the patients are followed for 26 weeks on a fixed dose of 0.54 g/kg/week in the&#xD;
      SCIG group (total 14 g/kg) and 2 g/kg/4week in the IVIG group (total 14 g/kg). The patients&#xD;
      automatically continue in fase II in which treatment is reduced every 12 weeks (90%, 75%,&#xD;
      50%, 25% and 0%) over a course 60 weeks. The patients are evaluated at every visit with&#xD;
      overall disability sum score (ODSS), grip strength, medical research council score&#xD;
      (MRC-score), INCAT-Sensory Sum Score (ISS), 10-meter-walk test (10-MWT), 6-spot-step test&#xD;
      (6-SST), 9-hole-peg test (9-HPT), quality of life (EQ-5D-5L), Fatigue Severity Scale (FSS),&#xD;
      Neuropathic Pain Symptom Inventory (NPSI), Rasch built overall disability scale (RODS) and&#xD;
      Life Quality Index (LQI) and blood samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disability</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>Evaluated with overall disability sum score (ODSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in grip strength</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>Grip strength (JAMAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in general muscle strength</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>MRC-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sensation</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>INCAT-Sensory Sum Score (ISS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking performance</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>10-meter-walk test (10-MWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking performance and imbalance</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>6-spot-step test (6-SST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dexterity</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>9-hole-peg test (9-HPT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>QoL (EQ-5D-5L incl. VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue severity</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>Fatigue Severity Scale (FSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain severity</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>Neuropathic Pain Symptom Inventory (NPSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disability</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>Rasch built overall disability scale (RODS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in treatment satisfaction</measure>
    <time_frame>Week 2 to 26</time_frame>
    <description>Life Quality Index (LQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum samples</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>Plasma IgG (IgG1, IgG2, IgG3, IgG4) Hematology: hemoglobin, reticulocyte count, haptoglobin, bilirubin, plasma haemoglobin, leukocyte count, thrombocyte count.&#xD;
Inflammatory biomarkers: sCD163 and neurofilament</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuations in the describing parameters (ODSS and RODS) in both groups (SCIG and IVIG) based on measurement at time points for treatment with IVIG</measure>
    <time_frame>Week 0 to 26</time_frame>
    <description>Average value of examinations made at week 0, 4 and 20 (prior to IVIG infusion) Average value of examinations made at week 2, 14 and 26 (2 weeks after IVIG infusion)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The lowest dose of IVIG or SCIG reached during the 60 weeks of reduction (Fase II).</measure>
    <time_frame>Week 26 to 86</time_frame>
    <description>Monitored on ODSS and the same secondary parameters as in week 0 to 26</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>CIDP - Chronic Inflammatory Demyelinating Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Patients treated with immunoglobulin intravenously (IVIG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immunoglobulin (PRIVIGEN) intravenously 2 g/kg/4week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with immunoglobulin subcutaneously (SCIG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immunoglobulin (HIZENTRA) subcutaneously 0.54 g/kg/week for 26 weeks. After this 60 weeks of reduction every 12 weeks (90%, 75%, 50%, 25% and 0%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunoglobulin</intervention_name>
    <description>Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.</description>
    <arm_group_label>Patients treated with immunoglobulin intravenously (IVIG)</arm_group_label>
    <arm_group_label>Patients treated with immunoglobulin subcutaneously (SCIG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfilling EFNS/PNS criteria for definite, probable or pure motor CIDP.&#xD;
&#xD;
          -  No previous treatment with IVIG or SCIG.&#xD;
&#xD;
          -  Age ≥ 18.&#xD;
&#xD;
          -  ODSS ≥ 2 - either (arm/leg): 1/1, 2/0 or 0/2 at the time of inclusion.&#xD;
&#xD;
        Clinical criteria for typical CIDP&#xD;
&#xD;
          -  Chronically progressive, stepwise, or recurrent symmetric proximal and distal weakness&#xD;
             and sensory dysfunction of all extremities, developing over at least 2 months; cranial&#xD;
             nerves may be affected.&#xD;
&#xD;
          -  Absent or reduced tendon reflexes in all extremities.&#xD;
&#xD;
        Criteria for pure motor CIDP • Pure motor affection; otherwise as for typical CIDP.&#xD;
&#xD;
        Electrophysiological criteria for CIDP&#xD;
&#xD;
          1. Motor distal latency prolongation ≥50% above ULN in two nerves (excluding median&#xD;
             neuropathy at the wrist from carpal tunnel syndrome), or&#xD;
&#xD;
          2. Reduction of motor conduction velocity ≥30% below LLN in two nerves, or&#xD;
&#xD;
          3. Prolongation of F-wave latency ≥30% above ULN in two nerves (≥50% if amplitude of&#xD;
             distal negative peak CMAP ≤80% of LLN values), or&#xD;
&#xD;
          4. Absence of F-waves in two nerves of these nerves have distal negative peak CMAP&#xD;
             amplitudes ≥20% of LLN + ≥1 other demyelinating parameter in ≥1 other nerve, or&#xD;
&#xD;
          5. Partial motor conduction block: ≥50% amplitude reduction of the proximal negative peak&#xD;
             CMAP relative to distal, if distal negative peak CMAP &gt;20% of LLN, in two nerves, or&#xD;
             in one nerve + ≥1 other demyelinating parameter in ≥1 other nerve, or&#xD;
&#xD;
          6. Abnormal dispersion (≥30% duration increase between the proximal and distal negative&#xD;
             peak CMAP) in ≥2 nerves, or&#xD;
&#xD;
          7. Distal CMAP duration (interval between onset of the first negative peak an return to&#xD;
             baseline of the last negative peak) increase in ≥1 nerve (median ≥6.6 ms, ulnar ≥6.7&#xD;
             ms, peroneal ≥7.6 ms, tibial ≥8.8 ms) + ≥1 other demyelinating parameter in ≥1 other&#xD;
             nerve&#xD;
&#xD;
        Electrophysiological criteria for probable CIDP&#xD;
&#xD;
        (a) ≥30% amplitude reduction of the proximal negative peak CMAP relative to distal,&#xD;
        excluding the posterior tibial nerve, if distal negative peak CMAP ≥20% of LLN, in two&#xD;
        nerves, or in one nerve + ≥1 other demyelinating parameter in ≥1 other nerve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of neuropathy&#xD;
&#xD;
          -  Increased risk of thromboembolism&#xD;
&#xD;
          -  Pregnancy (Plasma HCG is tested at inclusion in all fertile women)&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Severe medical disease&#xD;
&#xD;
          -  Other immune modulating treatment than low dose steroid (prednisolon &lt; 25 mg daily)&#xD;
             within the last 6 months prior to inclusion&#xD;
&#xD;
          -  Hepatitis B or C or HIV infection (screening at inclusion)&#xD;
&#xD;
          -  Known IgA deficiency&#xD;
&#xD;
          -  Known allergy to consents in PRIVIGEN or HIZENTRA&#xD;
&#xD;
          -  Body weight &gt; 120 kg&#xD;
&#xD;
        After treatment initiation:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Serious medical disease that affects treatment or examinations&#xD;
&#xD;
          -  Non-compliance to treatment&#xD;
&#xD;
          -  Initiation of other immune modulating therapy&#xD;
&#xD;
          -  Unacceptable side effects&#xD;
&#xD;
          -  Withdrawal of consent to participate (drop-out)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Andersen, MD,DMSc,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Markvardsen, MD, PhD</last_name>
    <phone>+45 20231903</phone>
    <email>larsmark@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Izabella Obál, Md, PhD</last_name>
      <phone>9766 2200</phone>
      <email>i.obal@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Andersen, DMSc</last_name>
      <email>hennande@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Lars Markvardsen, MD</last_name>
      <phone>+45 7846 3337</phone>
      <email>larsmark@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Markvardsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henning Andersen, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Rigshospitalet, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina D Jeppesen, MD,DMSc,PhD</last_name>
      <email>tina.dysgaard.jeppesen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Tina D Jeppesen, MD,DMSc,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Søren Sindrup, MD, DMSc</last_name>
      <phone>+45 6541 2485</phone>
      <email>soeren.sindrup@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunoglobulins, Intravenous</keyword>
  <keyword>Injections, Subcutaneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

